CSL Ltd (ASX: CSL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
CSL Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$137.10 billion
P/E Ratio
33.50
Dividend Yield
1.42%
Shares Outstanding
484.21 million
Earnings per share
5.450
Dividend per share
3.97
Year To Date Return
-0.71%
Earnings Yield
2.99%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
CSL Ltd (ASX: CSL)
Latest News
Earnings Results
CSL share price tumbles after FY25 guidance disappoints
Earnings Results
CSL shares on watch amid US$3b FY 2024 profit
Share Market News
5 things to watch on the ASX 200 on Tuesday
Healthcare Shares
A top ASX 200 share with 'resilient earnings' growth to buy now
Healthcare Shares
Down 40%, but I'm backing this ASX 200 stock to fly like the CSL share price
Healthcare Shares
Here's how I think the CSL share price might end 2024
ETFs
ASX ETFs vs shares: Do investors prefer one over the other?
Best Shares
Which ASX 200 market sector has been the best performer over 10 years?
Blue Chip Shares
Buy CSL and these ASX 200 blue chip shares now
Healthcare Shares
1 top ASX healthcare stock I'd be happy to hold through a recession
Healthcare Shares
Will next week's earnings slingshot CSL shares higher?
Healthcare Shares
Why now is an 'attractive buying opportunity' for CSL shares
Frequently Asked Questions
-
CSL was listed on the ASX in June 1994.
-
CSL has paid twice yearly dividends every year since late 1997, a little over three years after the company’s initial listing on the ASX. Up until early 2005, CSL’s dividends were all fully franked. Since then, franking credits have been intermittent.
Since 2021 CSL has paid an unfranked interim dividend in April and a 10% franked final dividend in September/October.
-
CSL has a dividend reinvestment plan, however, it has not been active since 2004. Instead, CSL periodically executes share buybacks as a way of delivering additional returns for shareholders.
-
CSL originally floated in 1994 at $2.30 per share. However, taking into account share buybacks, the adjusted entry price is equivalent to around 76 cents.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 09 Sep 2024 | $2.1746 | 0.00% | Final | 02 Oct 2024 |
| 11 Mar 2024 | $1.7989 | 0.00% | Interim | 03 Apr 2024 |
| 11 Sep 2023 | $2.0078 | 6.42% | Final | 04 Oct 2023 |
| 09 Mar 2023 | $1.6215 | 0.00% | Interim | 05 Apr 2023 |
| 06 Sep 2022 | $1.7583 | 10.00% | Final | 05 Oct 2022 |
| 07 Mar 2022 | $1.4229 | 0.00% | Interim | 06 Apr 2022 |
| 02 Sep 2021 | $1.5897 | 10.00% | Final | 30 Sep 2021 |
| 04 Mar 2021 | $1.3491 | 0.00% | Interim | 01 Apr 2021 |
| 10 Sep 2020 | $1.4696 | 0.00% | Final | 09 Oct 2020 |
| 11 Mar 2020 | $1.4713 | 0.00% | Interim | 09 Apr 2020 |
| 10 Sep 2019 | $1.4545 | 0.00% | Final | 11 Oct 2019 |
| 13 Mar 2019 | $1.2032 | 0.00% | Interim | 12 Apr 2019 |
| 11 Sep 2018 | $1.2782 | 0.00% | Final | 12 Oct 2018 |
| 14 Mar 2018 | $1.0050 | 0.00% | Interim | 13 Apr 2018 |
| 12 Sep 2017 | $0.0000 | 0.00% | Final | 13 Oct 2017 |
| 15 Mar 2017 | $0.8378 | 0.00% | Interim | 13 Apr 2017 |
| 13 Sep 2016 | $0.8867 | 0.00% | Final | 07 Oct 2016 |
| 23 Mar 2016 | $0.8147 | 0.00% | Interim | 15 Apr 2016 |
| 07 Sep 2015 | $0.8999 | 0.00% | Final | 02 Oct 2015 |
| 16 Mar 2015 | $0.7439 | 0.00% | Interim | 10 Apr 2015 |
| 08 Sep 2014 | $0.6485 | 0.00% | Final | 03 Oct 2014 |
| 05 Mar 2014 | $0.5888 | 0.00% | Interim | 04 Apr 2014 |
| 09 Sep 2013 | $0.5698 | 0.00% | Final | 04 Oct 2013 |
| 05 Mar 2013 | $0.3406 | 0.00% | Interim | 05 Apr 2013 |
| 17 Sep 2012 | $0.3290 | 0.00% | Final | 12 Oct 2012 |
| 14 Mar 2012 | $0.2520 | 0.00% | Interim | 13 Apr 2012 |
| 19 Sep 2011 | $0.3210 | 6.23% | Final | 14 Oct 2011 |
| 08 Mar 2011 | $0.2450 | 0.00% | Interim | 08 Apr 2011 |
| 13 Sep 2010 | $0.3308 | 15.96% | Final | 08 Oct 2010 |
| 09 Mar 2010 | $0.2450 | 0.00% | Interim | 09 Apr 2010 |
| 14 Sep 2009 | $0.2800 | 0.00% | Final | 09 Oct 2009 |
| 17 Sep 2007 | $0.4675 | 58.82% | Final | 12 Oct 2007 |
| 14 Mar 2006 | $0.1960 | 0.00% | Interim | 13 Apr 2006 |
| 30 Aug 2005 | $0.0753 | 23.64% | Special | 10 Oct 2005 |
| 30 Aug 2005 | $0.3000 | 100.00% | Final | 10 Oct 2005 |
| 29 Mar 2004 | $0.1200 | 100.00% | Interim | 13 Apr 2004 |
CSL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About CSL Ltd
CSL Limited (ASX: CSL) is an Australian-based global biotechnology company that develops and delivers biotherapies and vaccines to protect public health and help people with life-threatening medical conditions live full lives.
CSL has been in operation for more than a century and was listed on the ASX in 1994. Today, the blue-chip healthcare company is one of the largest on the ASX.
CSL’s operational businesses include CSL Behring, CSL Seqirus and CSL Vifor. Its Plasma business operates one of the largest plasma collection networks in the world. CSL is recognised for its global leadership in three main areas: rare and serious diseases, vaccine development, and iron deficiency and nephrology (kidney research).
The company operates in over 40 countries, predominantly Australia, the United States, Germany, the United Kingdom, and Switzerland.
CSL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 03 Dec 2024 | $284.62 | $3.99 | 1.42% | 868,457 | $281.99 | $285.98 | $278.00 |
| 02 Dec 2024 | $280.63 | $-1.59 | -0.56% | 479,294 | $282.18 | $282.86 | $279.00 |
| 29 Nov 2024 | $282.22 | $-2.96 | -1.04% | 700,043 | $282.33 | $283.24 | $280.70 |
| 28 Nov 2024 | $285.18 | $4.44 | 1.58% | 599,680 | $282.90 | $286.56 | $282.47 |
| 27 Nov 2024 | $280.74 | $0.52 | 0.19% | 524,613 | $282.50 | $283.00 | $280.26 |
| 26 Nov 2024 | $280.22 | $-0.85 | -0.30% | 809,069 | $281.47 | $281.68 | $277.91 |
| 25 Nov 2024 | $281.07 | $4.60 | 1.66% | 1,257,089 | $279.73 | $281.94 | $279.23 |
| 22 Nov 2024 | $276.47 | $2.75 | 1.00% | 1,041,209 | $277.13 | $278.81 | $275.00 |
| 21 Nov 2024 | $273.72 | $-0.58 | -0.21% | 997,247 | $275.67 | $276.85 | $273.07 |
| 20 Nov 2024 | $274.30 | $2.94 | 1.08% | 688,603 | $272.00 | $274.30 | $270.02 |
| 19 Nov 2024 | $271.36 | $-1.09 | -0.40% | 1,121,461 | $272.45 | $275.19 | $271.02 |
| 18 Nov 2024 | $272.45 | $-4.56 | -1.65% | 890,824 | $271.21 | $273.30 | $270.09 |
| 15 Nov 2024 | $277.01 | $-7.04 | -2.48% | 921,020 | $280.67 | $281.07 | $275.01 |
| 14 Nov 2024 | $284.05 | $-1.49 | -0.52% | 423,442 | $287.55 | $287.60 | $283.86 |
| 13 Nov 2024 | $285.54 | $-1.12 | -0.39% | 392,254 | $285.50 | $285.86 | $282.18 |
| 12 Nov 2024 | $286.66 | $-0.66 | -0.23% | 422,699 | $287.45 | $289.05 | $284.54 |
| 11 Nov 2024 | $287.32 | $2.03 | 0.71% | 518,725 | $285.40 | $287.70 | $285.01 |
| 08 Nov 2024 | $285.29 | $1.90 | 0.67% | 491,784 | $286.24 | $286.95 | $283.70 |
| 07 Nov 2024 | $283.39 | $-2.34 | -0.82% | 472,108 | $286.25 | $287.25 | $281.40 |
| 06 Nov 2024 | $285.73 | $1.74 | 0.61% | 280,971 | $286.36 | $287.19 | $283.86 |
| 05 Nov 2024 | $283.99 | $-2.35 | -0.82% | 346,546 | $286.92 | $288.00 | $283.67 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 31 Oct 2024 | Paul McKenzie | Sell | 4,000 | $1,148,600 |
On-market trade.
|
| 30 Oct 2024 | Paul McKenzie | Issued | 38,065 | $10,942,164 |
Issue of securities. 103,522 Performance Share Units
|
| 03 Sep 2024 | Paul McKenzie | Sell | 3,779 | $1,149,997 |
On-market trade.
|
| 03 Sep 2024 | Paul McKenzie | Expiry | 10,742 | $3,287,374 |
As advised by the company. Lapsed, 73,732 Rights
|
| 03 Sep 2024 | Paul McKenzie | Buy | 8,275 | $2,532,398 |
Conversion of securities.
|
| 03 Sep 2024 | Paul McKenzie | Exercise | 8,275 | $2,532,398 |
Conversion of securities. 65,457 Rights
|
| 21 Aug 2024 | Megan Clark | Issued | 264 | $80,277 |
Director remuneration. vwap, 264 Rights
|
| 21 Aug 2024 | Carolyn Hewson | Issued | 352 | $107,036 |
Director remuneration. vwap, 352 rights
|
| 21 Aug 2024 | Alison Watkins | Issued | 308 | $93,656 |
Director remuneration. VWAP, 308 Rights
|
| 21 Aug 2024 | Brian McNamee | Issued | 625 | $190,050 |
Director remuneration. vwap, 625 Rights
|
| 21 Aug 2024 | Robert Cuthbertson | Issued | 264 | $80,277 |
Director remuneration. 264 Rights, vwap
|
| 21 Aug 2024 | Duncan Maskell | Issued | 220 | $66,897 |
Director remuneration. vwap, 220 rights
|
| 21 Aug 2024 | Marie McDonald | Issued | 176 | $53,518 |
Director remuneration. 176 Rights, vwap
|
| 21 Aug 2024 | Samantha (Sam) Lewis | Issued | 220 | $66,897 |
Director remuneration. vwap, 220 Rights
|
| 16 Aug 2024 | Megan Clark | Buy | 145 | $44,274 |
Conversion of securities.
|
| 16 Aug 2024 | Megan Clark | Exercise | 145 | $44,274 |
Conversion of securities.
|
| 16 Aug 2024 | Samantha (Sam) Lewis | Buy | 114 | $34,808 |
Conversion of securities.
|
| 16 Aug 2024 | Samantha (Sam) Lewis | Exercise | 114 | $34,808 |
Conversion of securities.
|
| 16 Aug 2024 | Marie McDonald | Exercise | 145 | $44,274 |
Conversion of securities.
|
| 16 Aug 2024 | Marie McDonald | Buy | 145 | $44,274 |
Conversion of securities.
|
| 16 Aug 2024 | Duncan Maskell | Buy | 338 | $103,204 |
Conversion of securities.
|
| 16 Aug 2024 | Duncan Maskell | Exercise | 338 | $103,204 |
Conversion of securities.
|
| 16 Aug 2024 | Robert Cuthbertson | Buy | 145 | $44,274 |
Conversion of securities.
|
| 16 Aug 2024 | Robert Cuthbertson | Exercise | 145 | $44,274 |
Conversion of securities.
|
| 16 Aug 2024 | Brian McNamee | Exercise | 343 | $104,731 |
Conversion of securities.
|
| 16 Aug 2024 | Brian McNamee | Buy | 343 | $104,731 |
Conversion of securities.
|
| 16 Aug 2024 | Alison Watkins | Exercise | 169 | $51,602 |
Conversion of securities.
|
| 16 Aug 2024 | Alison Watkins | Buy | 169 | $51,602 |
Conversion of securities.
|
| 16 Aug 2024 | Carolyn Hewson | Exercise | 193 | $58,930 |
Conversion of securities.
|
| 16 Aug 2024 | Carolyn Hewson | Buy | 193 | $58,930 |
Conversion of securities.
|
| 21 Feb 2024 | Samantha (Sam) Lewis | Issued | 114 | $32,190 |
Director remuneration. VWAP
|
| 16 Feb 2024 | Megan Clark | Buy | 145 | $41,180 |
Conversion of securities.
|
| 16 Feb 2024 | Megan Clark | Exercise | 145 | $41,180 |
Conversion of securities. 145 Rights
|
| 16 Feb 2024 | Duncan Maskell | Exercise | 339 | $96,276 |
Conversion of securities. 338 Rights
|
| 16 Feb 2024 | Duncan Maskell | Buy | 339 | $96,276 |
Conversion of securities.
|
| 16 Feb 2024 | Marie McDonald | Buy | 145 | $41,180 |
Conversion of securities.
|
| 16 Feb 2024 | Marie McDonald | Exercise | 145 | $41,180 |
Conversion of securities. 145 Right
|
| 16 Feb 2024 | Carolyn Hewson | Buy | 193 | $54,812 |
Conversion of securities.
|
| 16 Feb 2024 | Carolyn Hewson | Exercise | 193 | $54,812 |
Conversion of securities. 193 Rights
|
| 16 Feb 2024 | Alison Watkins | Exercise | 169 | $47,996 |
Conversion of securities. 169 Rights
|
| 16 Feb 2024 | Alison Watkins | Buy | 169 | $47,996 |
Conversion of securities.
|
| 16 Feb 2024 | Brian McNamee | Buy | 343 | $97,412 |
Conversion of securities.
|
| 16 Feb 2024 | Brian McNamee | Exercise | 343 | $97,412 |
Conversion of securities. 343 Rights
|
| 16 Feb 2024 | Robert Cuthbertson | Exercise | 145 | $41,180 |
Conversion of securities. 145 Rights
|
| 16 Feb 2024 | Robert Cuthbertson | Buy | 145 | $41,180 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Carolyn Judith Hewson | Non-Executive Director | Dec 2019 |
Ms Hewson is a former investment banker with over 35 years of experience in the finance sector. She was previously an executive director of Schroders Australia Limited and has financial markets, risk management and investment management expertise. She has non-executive experience in several sectors bringing experience and insight on strategy, capital management and portfolio optimisation through cycles, financial and non-financial risk, social value, organisational culture, and the changing external environment. She is Chair of the Corporate Governance Committee, Member of the Risk Management Committee and Human Resources Committee.
|
| Ms Alison Mary Watkins | Non-Executive Director | Aug 2021 |
Ms Watkins brings experience to the Board through the executive and non executive roles she has held across industries, including manufacturing, agriculture, consumer goods, retail and financial services. She is Chair of Risk Management Committee and Member of the Human Resources Committee.
|
| Dr Brian Anthony McNamee | Non-Executive DirectorNon-Executive Chairman | Jan 1990 |
Dr McNamee has executive experience in the biopharmaceutical industry, with a focus on strategy and creating shareholder value. Since leaving his executive role at CSL, Dr McNamee has served as a senior advisor to private equity group Kohlberg Kravis Roberts. He has also pursued several private equity and interests in small cap healthcare companies, and in 2014 served on the panel of the Australian Government's Financial System Inquiry. In 2009, he was made an Officer of the Order of Australia for service to business and commerce. He is Member of the Innovation and Development Committee and Corporate Governance.
|
| Dr Robert Andrew Cuthbertson | Non-Executive Director | Oct 2018 |
Dr Cuthbertson has over 35 years of experience in medical research and biotech development with biopharmaceutical companies and medical organisations. He also has non-executive director experience. In 2016, he was made an Officer of the Order of Australia and appointed Enterprise Professor at the University of Melbourne. He is Chair of the Innovation and Development Committee and Member of the Corporate Governance Committee.
|
| Ms Marie Elizabeth McDonald | Non-Executive Director | Aug 2013 |
Ms McDonald has executive and non-executive experience in several sectors including law, medical research, manufacturing, and chemicals. Through these roles, Ms McDonald brings experience and insight on financial markets, risk and compliance and change management. Ms McDonald is a former lawyer with over 30 years of experience in the legal sector. She was previously a Partner of Ashurst, specialising in mergers and acquisitions and corporate governance. She is member of the Risk Management Committee and Human Resources Committee.
|
| Ms Samantha (Sam) Louise Lewis | Non-Executive Director | Jan 2024 |
Ms Lewis Ms Lewis is a non-executive director serving on boards of ASX 100 companies since 2014. Ms Lewis has experience in accounting, finance, auditing, risk management, corporate governance, capital markets and due diligence. Prior to becoming a Non-executive Director, Ms Lewis spent 24 years with Deloitte, including 14 years as a Partner. In that role, she acted as lead auditor of several Australian listed entities and provided accounting and transactional advisory services including due diligence, IPOs, and debt/equity raisings. Ms Lewis has experience working with companies in the manufacturing, retail, and industrial sectors. She is member of the Risk Management Committee.
|
| Dr Megan Elizabeth Clark | Non-Executive Director | Feb 2016 |
Dr Clark has executive and non-executive experience across a range of sectors, including scientific research, health, investment banking and financial services, education, and mining. Through her roles, Dr Clark brings a strategic perspective and global experience, with a focus on risk and proven health, safety and environment and technology performance. In 2014, Dr Clark was made a Companion of the Order of Australia for eminent service to scientific research and development. He is Chair of the Human Resources Committee, and Member of the Corporate Governance and Innovation and Development Committee.
|
| Dr Paul McKenzie | Chief Operating OfficerExecutive DirectorChief Executive OfficerManaging Director | Dec 2022 |
Dr McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing organisations through growth and transformation. He changed CSL's global end to end operations, advanced CSL Seqirus differentiated portfolio strategy, and led CSL Plasma through COVID-19 challenges while surpassing plasma collection volumes beyond pre-pandemic levels. Prior to joining CSL, Dr McKenzie was executive vice president of Pharmaceutical Operations & Technology at Biogen. He also served in a range of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb, and Merck. He is also Member of the Innovation and Development Committee.
|
| Ms Elaine Sorg | Non-Executive Director | Sep 2024 |
Ms Sorg has more than 35 years experience as a senior executive with pharmaceutical companies including AbbVie and Eli Lilly. Prior to her retirement in 2023, Ms Sorg was Senior Vice President for AbbVie and President of AbbVies US commercial operations. She is currently on the Deans Advisory Council at Purdue University School of Pharmacy and Pharmaceutical Science, and is a Senior Advisor at the Boston Consulting Group, where she advises global health care clients on business-critical strategies and decisions.
|
| Ms Fiona Mead | Company SecretaryHead of Group Governance | Jun 2018 |
-
|
| Kate Priestman | Chief Corporate & External Affairs Officer |
-
|
|
| Joy Linton | Chief Financial Officer |
-
|
|
| Roanne Parry | Chief Human Resources Officer |
-
|
|
| Fiona Mead | Company SecretaryHead of Group Governance |
-
|
|
| Ken Lim | Executive Vice President and Chief Strategy Officer |
-
|
|
| Mark Hill | Executive Vice President Chief Digital Information Officer |
-
|
|
| Andy Schmeltz | Executive Vice President CSL Behring |
-
|
|
| Bill Mezzanotte | Executive Vice President Head of Research & Development |
-
|
|
| Greg Boss | Executive Vice President Legal and CSL Group General Counsel |
-
|
|
| Dave Ross | Senior Vice President and General Manager CSL Seqirus |
-
|
|
| Herve Gisserot | Senior Vice President and General Manager CSL Vifor |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 162,829,983 | 33.69% |
| P Morgan Nominees Australia Pty Limited | 86,779,316 | 17.96% |
| Citicorp Nominees Pty Limited | 46,160,603 | 9.55% |
| Bnp Paribas Nominees Pty Ltd <Agency Lending A/C> | 11,290,713 | 2.34% |
| National Nominees Limited | 8,358,823 | 1.73% |
| BNP Paribas Noms Pty Ltd | 7,126,947 | 1.47% |
| Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 5,206,440 | 1.08% |
| HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 3,491,236 | 0.72% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 2,862,019 | 0.59% |
| Netwealth Investments Limited <Wrap Services A/C> | 2,822,828 | 0.58% |
| Australian Foundation Investment Company Limited | 2,239,500 | 0.46% |
| Solium Nominees (Australia) Pty Ltd <Allocated A/C> | 1,682,180 | 0.35% |
| Custodial Services Limited <Beneficiaries Holding A/C> | 1,611,222 | 0.33% |
| Argo Investments Limited | 1,341,509 | 0.28% |
| Mutual Trust Pty Ltd | 1,051,510 | 0.22% |
| BNP Paribas Noms (Nz) Ltd | 1,024,918 | 0.22% |
| Solium Nominees (Australia) Pty Ltd <Vsa A/C> | 796,200 | 0.16% |
| D W S Nominees Pty Ltd | 793,208 | 0.17% |
| IOOF Investment Services Limited <Ioof Idps A/C> | 687,223 | 0.14% |
| Ioof Investment Services Limited <Ips Superfund A/C> | 669,103 | 0.14% |
